Thank-you OncLive. Incredibly important data by Dr Choong regarding the detrimental impact of endocrine therapy omission in pts with residual ER+ BC after neoadjuvant chemotherapy (regardless of HER2 status)

Great to have the #Accru breast team together at #SABCS2022

Dr. Matthew Goetz discusses his #ELAINE2 #BreastCancer research poster presented at SABCS.

Women with #BreastCancer in one breast may be at higher risk of developing cancer in the opposite breast if they have a #BRCA1, #BRCA2 or CHEK2 mutation, according to a study led by Mayo Clinic Comprehensive Cancer Center. Read more: mayocl.in/3XGBuVN

Register now to attend OncLive.com's Institutional Perspectives in Cancer virtual event for #BreastCancer, led by Mayo Clinic experts Matthew Goetz and Judy Boughey. See the overview, featured topics and register here: mayocl.in/3Ca6IMv

Congratulations to Dr. Sid Yadav and Fergus Couch on their ASCO presentation demonstrating that P/LP missense variants carry same lifetime breast cancer risk as DBD truncating variants

It was a pleasure to present these data. Critically important, as any biomarker needs to be fully validated before being used to select patients. In this case, these biomarkers are prognostic but clearly not predictive of abemacicib benefit.

Alliance for Clinical Trials in Oncology plenary session. New group chair Dr Eva Galanis Mayo Clinic Comprehensive Cancer Center opens the plenary session.

Jack Cuzick shows the benefit of anastrozole in IBIS -II according to baseline estradiol levels at the SABCS McGuire lecture. Potentially practice changing.

IT’S GREAT TO BE A MICHIGAN WOLVERINE! #GoBlue

📣What is the role of immune activation on the prognosis of early #TNBC if chemo is not given? We evaluated ~ 2,000 pts w eTNBC from 13 institutions around the globe to answer this. See our results published today in JAMA jamanetwork.com/journals/jama/…

What is the impact of endocrine therapy omission in ER low (IHC 1-10%) breast cancer? Dr. Grace Choong presents data at ASCO 2024 regarding the detrimental impact of ET omission in this group of pts with tumors traditionally characterized as biologically similar to TNBC

Congratulations to Dr. Roberto Leon Ferre for your ASCO Conquer Cancer Advanced Clinical Research Award.